Nuvation Bio Inc - Ordinary Shares - Class A Stock News

Shares of Nuvation Bio (NUVB 14.13%) were skyrocketing 15.7% higher as of 11:20 a.m. ET on Tuesday.

NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced it has enrolled the first patient in TRUST-IV (NCT07154706), a Phase 3 study evaluating the efficacy and safety of IBTROZI™ (taletrectinib), a next-generation ROS1 inhibitor, versus placebo for the adjuvant treatment of pat...

Today, I am highlighting three biotech stocks I like in the current market that are trading at under $10.00 a share. The options on these stocks are also lucrative and liquid, making them well-suited for consistent covered call trades. Covered call strategies offer downside protection in the underperforming, high-beta biotech sector, supporting a rinse, wash, and repeat approach.

NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved IBTROZITM (taletrectinib) for the treatment of adult patients with ROS1-positive (ROS1+) unresectable, advanced and/or recurrent non-small cell lung ca...

Nuvation Bio is a compelling long-term biotech investment following FDA approval and the strong early launch of IBTROZI (taletrectinib) for ROS1+ NSCLC. IBTROZI's superior efficacy, rapid uptake, and NCCN Preferred Agent status position NUVB to capture significant market share in a niche oncology market. NUVB boasts a robust balance sheet with $600M net cash, a deep pipeline, and proven leaders...

NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced new and updated results from the pivotal Phase 2 TRUST-I and TRUST-II studies evaluating IBTROZI™ (taletrectinib) for the treatment of adult patients with locally advanced or metastatic ROS1-positive (ROS1+) non-small cell ...

Nuvation Bio is a Buy after FDA approval of Ibtrozi, a highly selective ROS1+ NSCLC treatment with strong clinical results and brain metastasis efficacy. Ibtrozi demonstrated superior response rates and progression-free survival compared to established TKIs, positioning it as a leading contender in a growing market. Financials are solid with $247M cash, low price-to-book, and a conservative $70...

NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio, and Philippe Sauvage, Chief Financial Officer of Nuvation Bio, will participate in three upcoming investor conferences, including fires...